Business
Curis to Present at Upcoming Healthcare Conference in April
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation.
About this update from Curis, Inc.
[{"type":"text","content":"LEXINGTON, Mass., April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation.","length":442,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Curis, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Curis, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":207,"url":"https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bs_Ynz1IdxzlIjT8sYZeig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a","width":400,"height":207}},"href":"https://mma.prnewswire.com/media/607886/Curis_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"All Bets on IRAK4 Fireside Chat:","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Time: 4:30 pm ET (1:30 pm PT)","length":29,"tagName":"p"}]},{"val":[{"type":"text","content":"Fireside Chat Webcast","length":21,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":50,"olType":false},{"type":"text","content":"Curis Company Presentation:","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Time: 5:00 pm ET (2:00 pm PT)","length":29,"tagName":"p"}]},{"val":[{"type":"text","content":"Corporate Presentation Webcast","length":30,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":59,"olType":false},{"type":"text","content":"The live webcast and archived replay will be available and can also be accessed from the Events & Presentations section of Curis's website.","length":152,"tagName":"p"},{"type":"text","content":"About Curis, Inc.","length":17,"tagName":"p"},{"type":"text","content":"Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) in patients with relapsed/...